论文部分内容阅读
目的探讨蛋白激酶Cη(PKCη)在非小细胞肺癌(NSCLC)中的表达及临床意义。方法采用免疫组化方法检测93例NSCLC组织及56例癌旁组织中PKCη的表达水平,分析PKCη的表达与临床病理特征和预后的关系。结果 NSCLC组织PKCη的阳性表达率为63.44%,高于癌旁组织的21.27%(P<0.01)。PKCη的表达与患者的性别、年龄、吸烟状态、组织学类型以及肿瘤T分期无明显相关性(P>0.05),而与肿瘤的分化程度、病理分期及淋巴结转移有关(P<0.05或P<0.01)。PKCη阳性表达组总生存期低于阴性表达组(P<0.05)。结论 PKCη在NSCLC中表达较高,与肿瘤的分化程度、转移及患者的预后密切有关。
Objective To investigate the expression of protein kinase Cη (PKCη) in non-small cell lung cancer (NSCLC) and its clinical significance. Methods The expression of PKCη in 93 NSCLC tissues and 56 adjacent non-cancerous tissues was detected by immunohistochemistry. The relationship between the expression of PKCη and clinicopathological features and prognosis was analyzed. Results The positive expression rate of PKCη in NSCLC tissues was 63.44%, which was higher than that in adjacent tissues (21.27%, P <0.01). There was no significant correlation between the expression of PKCη and the gender, age, smoking status, histological type and tumor T stage (P> 0.05), but correlated with tumor differentiation, pathological stage and lymph node metastasis (P <0.05 or P < 0.01). The overall survival of PKCn positive expression group was lower than that of negative expression group (P <0.05). Conclusions PKCη is highly expressed in NSCLC, which is closely related to the degree of tumor differentiation and metastasis and the prognosis of patients.